본문 바로가기 주메뉴 바로가기
  • HOME
  • Public Relations
  • GC Cell News

GC Cell News

GC Cell Completes pct for entry into the global market
2021-08-31
GC Cell Completes pct for entry into the global market
GC Cell has completed two PCT international patent applications for Immuncell-LC injection and Mesothelin-targeted CAR-T to advance into the global market.
With these PCT international patent applications, GC Cell has secured exclusive licenses for Immuncell-LC injection and Mesothelin-targeted CAR-T, which are major R&D pipelines, in major foreign countries. We plan to highlight GC Cells unique technological differentiation with enhanced intellectual property rights in overseas markets as well as domestic markets.
In particular, we plan to actively target the US, Chinese, and Indian markets through Immuncell-LC injection, and we are already negotiating with a number of partners in these countries, such as technology transfer. The Immuncell-LC injection was approved by the Ministry of Food and Drug Safety in August 2007. In July 2020, a domestic patent was registered as ‘Activated lymphocyte including cytokine-induced killer Cell and preparing method thereof’.
In addition, ‘Mesothelin-specific chimeric antigen receptor and T lymphocyte expressing this chimeric antigen receptor’ was patented in Korea in February 2021, and PCT international applications were filed in 4 countries (USA, Europe, China, and Japan) in July 2021. The CAR-T treatment showed breakthrough results in animal experiments on pancreatic cancer, and preparations are underway to enter clinical trials in the US in the first half of next year.
GC Cell has filed this PCT international application to advance into overseas markets for major R&D pipelines. Through this, we will do our best to complete the strategy to enter the global market by strengthening the technological competitiveness and corporate values of GC Cell on the international stage.
Next
Does not exist
Previous
GC Cell Immuncell-LC Injection is Reborn as Advanced Biopharmaceuticals